Posted on July 30, 2018 by Sitemaster
We have recently started to see a flurry of publications of papers suggesting that biparametric MRI (bpMRI) scans may be “better” — or at least more cost-effective — than multiparametric MRI (mpMRI) scans in the diagnosis of localized forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: biparametric, bpMRI, mpMRI, MRI, multiparametric, scan | Leave a comment »
Posted on December 7, 2017 by Sitemaster
Because the success or failure of salvage radiation (SRT) hinges upon whether micrometastases are already systemic at the time of treatment, evidence that the cancer is still local improves the odds that SRT will be successful. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: mpMRI, PET/CT, PSMA, radition, salvage, therapy | 1 Comment »
Posted on October 24, 2017 by Sitemaster
Some people aren’t going to be happy about the following data, but they come from one of the most sophisticated prostate cancer imaging centers in the world … and they make it very clear indeed that multiparametric MRI scanning (mpMRI) is less than perfect in identification of risk for prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: accuracy, false, mpMRI, negative, result, scan | 2 Comments »
Posted on October 19, 2017 by Sitemaster
A new paper just published on line in the journal PLoS One is entitled, “Association between a 17-gene genomic prostate score and a multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa)”. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: genomic, mpMRI, MRI, multi-parametric, risk, scan, score, test | Leave a comment »
Posted on October 4, 2017 by Sitemaster
At least one paper has stated that some 40 percent of men diagnosed with low-risk prostate cancer here in the US are now being initially managed on active surveillance. If active surveillance is being done properly, this is a good thing! However, … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: active, mpMRI, MRI, multiparametric, surveillance | 10 Comments »
Posted on April 14, 2017 by Sitemaster
Recently posted on the UroToday web site are summaries of four “state-of-the-art” lectures on prostate cancer and its management presented a couple of weeks ago at the annual meeting of the European Association of Urology is London. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: hereditary, mCRPC, mpMRI, review, state-of-the-art | 10 Comments »
Posted on March 8, 2017 by Sitemaster
As we have been pointing out for a while, the actual and potential roles for the use of multiparametric MRI (mpMRI) scanning in the diagnosis of prostate cancer is changing, and quite fast too. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, mpMRI, MRI, multiparametric, risk, scan | 1 Comment »
Posted on January 20, 2017 by Sitemaster
A newly published paper in the American Journal of Roetgenology provides an early data set on the application of 3 T multiparameric MRI scans in monitoring men on active surveillance (as opposed to the use of serial biopsies). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, monitoring, mpMRI, MRI, multiparametric, surveillance | 1 Comment »
Posted on January 19, 2017 by Sitemaster
The PROMIS study is a UK-based study designed to confirm earlier data suggesting that having a multiparametric MRI (mpMRI) scan could really help to decide which men needed a prostate biopsy because they really did or didn’t have prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: biopsy, mpMRI, MRI, multiparametric, PROMIS, trial | 10 Comments »
Posted on September 12, 2016 by Sitemaster
A new article in the Journal of Urology has provided us with some initial insight into the value of multiparametric MRIs (mpMRIs) in monitoring progression of patients on active surveillance protocols. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, biopsy, fusion, mpMRI, MRI, MRI/TRUS, multiparametric, surveillance | 1 Comment »
Posted on August 29, 2016 by Sitemaster
The degree to which the PCA3 test is a useful tool in assessment of risk for clinically significant prostate cancer prior to biopsy has never, really, been entirely clear. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, mltiparametric, mpMRI, MRI, PCA3, risk | 2 Comments »
Posted on June 7, 2016 by Sitemaster
Another presentation at the ASCO annual meeting yesterday morning came from the PROMIS trial in the UK. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: accuracy, biopsy, Diagnosis, mpMRI, triage | 5 Comments »
Posted on February 25, 2014 by Sitemaster
A new paper in Urology suggests that combination of data from multiparametric magnetic resonance imaging (mpMRI) with traditional risk factors (Gleason score, clinical stage, PSA level, etc.) may be able to improve identification of men at risk for clinically significant prostate cancer at time of diagnosis. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: criteria, Epsetin, mpMRI, MRI, multiparametric, risk | Leave a comment »
Posted on June 15, 2013 by Sitemaster
An article in The Daily Telegraph in the UK this morning addresses a variety of issues related to the difficulties associated with the use of TRUS-guided prostate biopsy to diagnose localized and locally advanced prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: accuracy, biopsy, Diagnosis, mpMRI, MRI, multiparametric, scan | 1 Comment »